Breast 

SWOG S0226  Protocol  AE Flowsheet  (7/1/09) Phase III Randomized Trial of Anastrozole vs. Anastrozole and Fulvestrant as First-Line Therapy for Post Menopausal Women with Metastatic Breast Cancer

 SWOG JMA.17R     Protocol  (5/8/09)A Double Blind Randomization To Letrozole or Placebo For Women Previously Diagnosed with Primary Breast Cancer Completing Five Years of Adjuvant Aromatase Inhibitor Either as Initial Therapy or After Tamoxifen (including those in the MA.17 study)

CTSU N0434 (MA.27D)    Protocol   Association of Breast Density Changes, Plasma Hormone Changes and Breast Cancer Recurrence (Companion MA.27D)

RTOG 98-04    Protocol   Phase III Trial of Tamoxifen Alone vs. Tamoxifen Plus XRT for Good Risk Duct Carcinoma In-Situ (DCIS) of the Female Breast

NSABP B-42 Protocol  (1/6/2010) Treatment Calendar  AE Flowsheet   A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer

SWOG S0307  Protocol    Treatment Calendar-Arm 1   TC-Arm 2   TC-Arm 3   (2/1/10)     Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer

IBCSG 24-02    Protocol   Treatment Calendar-Arm A   Arm B   Arm C  A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer

NSABP B-40 Protocol(6/30/10) Treatment Calendar Group 1A  1B  Grp2A  2B  Grp3A   3B     A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens

CTSU CALGB 40302  Protocol  (Closure 07/14/10) Endocrine Therapy with or without Inhibition of EGF and HER2 Growth Factor Receptors:   A Randomized, Double-Blinded, Placebo-controlled Phase III Trial of Fulvestrant with or without Lapatinib for Postmenopausal Women with Hormone Receptor Positive Advanced Breast Cancer

CTSU PACCT-1   TAILORx    Protocol   Treatment Calendar Program for the Assessment of Clinical Cancer Tests (PACCT-1):  Trial Assigning Individualized Options for Treatment:  The TAILORx Trial

SWOG S0622 Protocol    Treatment Calendar-Arm 1   Arm 2 (12/15/10)Phase II Studies of Two Different Schedules of Dasatinib (NSC-732517) in Bone-Metastasis Predominant Metastatic Breast Cancer

IBCSG 25-02  Protocol    Treatment Calendar-Arm A   Arm B (closing 3/11/11) A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer

CTSU N063D ALTTO   Protocol    Treatment Calendar 2B lapa    Trt Calendar 2B Lapa/tras   Trt Calendar 2B tras    Trt Calendar 2B tras/lapa A Randomized, Multi-center, Open-label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer

CTSU C40502  Protocol  Treatment Calendar Arm A  Arm B  Arm C  Physician letter  Participant letter  (permanent closure 11/30/2011) A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nonoparticle Albumin Bound NAB-Paclitaxel or Ixabepilone with or without Bevacizumab as First-line Therapy for Locally Recurrent or Metastatic Breast Cancer

CTSU C40503    Protocol   Treatment Calendar  (permanent closure 11/30/11)Endocrine Therapy With or Without Anti-VEGF Therapy:  A Randomized Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab for Women with Hormone Receptor-Positive Advanced Breast Cancer

SWOG S0221 Protocol   Antioxidant Use  (permanent closure 1/15/12) Treatment Calendar Arm 1   TC-Arm 2   TC-Arm 3     TC-Arm 4    TC-Arm 6 Phase III Trial of Continuous Schedule AC + G vs. Q-2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Postoperative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Cancer

Colorectal  

NSABP LTS-01    Protocol   Patient Reported Outcomes in Long-term Survivors with Colon and Rectal Cancer

CTSU N0147     Protocol  A Randomized Phase III Trial of Irinotecan and/or Oxaliplatin Plus 5-Fluorouracil/Leucovorin with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer

SWOG S0600   Protocol  (11/10/10)Arm A FOLFIRI Arm A Irinotecan  Arm B FOLFIRI  Arm B Irinotecan    Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab or Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with Either FOLFOX, OPTIMOX, or XELOX

CTSU E5202  Protocol   Treatment calendar Arm A   Arm B   Arm C (closure 2/11/11)A Randomized Phase II Study Comparing 5-FU, Leucovorin and Oxaliplatin vs 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers

NSABP C11  Protocol  (permanent closure 12/16/11)NO further DATA submissionA Phase III Study Evaluating the Role of Perioperative Chemotherapy and Bevacizumab in Patients with Potentially Resectable Hepatic Colorectal Metastases

Gallbladder                                                                                                                                                          

GU                                          Bladder                                                                                                                                                                  SWOG 4B-95-1    Protocol    MVAC in Organ-Confined Bladder Cancer Based on p53 Status

Renal                                                                                                                                                                        CTSU E8802    Protocol    Phase II Trial of Doxorubicin and Gemcitabine in Metastatic Renal Cell Carcinoma with Sarcomatoid Features

Gynecologic 

Head and Neck                                                                                                                                                    

SWOG S0904  Protocol ( 8/1/2011)Randomized Phase II Study of Docetaxel Followed by Vandetanib (ZD6474) vs. Docetaxel Plus Vandetanib in patients with Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Leukemia     

SWOG E1905  Protocol    (4/29/11)A Randomized Phase II Trial of Azacitidine with or without the Histone Deacetylase Inhibitor Entinostat MS-275 for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (dysplastic type), and Acute Myeloid Leukemia with Multilineage Dysplasia

Lung

SWOG S0722      Protocol (9/15/11)A Phase II Trial of mTOR Inhibitor, Everolimus (RAD001;NSC-733504) in Malignant Pleural Mesothelioma (MPM)  

SWOG S0635    Protocol  AE Flowsheet   (8/15/11) Phase II Trial of the Combination of OSI-774(Erlotinib) and Bevacizumab in Stage IIIB and IV Bronchoalveolar Carcinoma (BAC) and Adencarcinoma with BAC Features (AdenoBAC)

SWOG S0636 Protocol  (9/1/10)A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Never-Smokers with Stage IIIB and IV Primary NSCLC Adenocarcinomas

RTOG R0623   Protocol   Phase II Trial of Combined Modality Therapy with Growth Factor Support for Patients with Limited Stage Small Cell Lung Cancer

NCCTG N0623    Protocol   Phase II Study of GW786034 in Patients with Malignant Pleural Mesothelioma

NCCTG N0528   Protocol   A Randomized Phase II Study of Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in Advanced Non-Small Cell Lung Cancer

 Lymphoma 

SWOG S0801    Protocol    Treatment Calendar   (12/15/10)  A Phase II Study of Iodine-131-Labeled Tositumomab in Combination With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Rituximab Therapy for Patients With Advanced Stage Follicular Non-Hodgkin’s Lymphoma

NCCTG N0683    Protocol   A Phase II Study of Sunitinib Malate for Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

SWOG S0601   Protocol  A Phase II Study of Combination Rituximab-CHOP and Bortezomib (Velcade) (R-CHOP-V) Induction Therapy Followed by Bortezomib Maintenance Therapy for Patients with Newly Diagnosed Mantle Cell Lymphoma

NCCTG N038H    Protocol   (3/06/09) Phase II Study of CCI-779 in Combination with Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Melanoma 

SWOG S0933 Protocol Treatment Calendar  AE Flowsheet   AE baseline  (11/15/11)Phase II Study of R04929097 in Advanced Melanoma

NCCTG N0675   Protocol   A Phase II Study of Temozolomide and Everolimus (RAD-001) Therapy for Metastatic Melanoma

SWOG E4697 Protocol    A Randomized, Placebo-Controlled Phase III Trial of Yeast Derived GM-CSF vs. Peptide Vaccination vs. GM-CSF Plus Peptide Vaccination vs. Placebo in Patients with No Evidence of Disease after Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma

Myeloma   

CTSU E4A03     Protocol     Randomized Phase III Study of CC-5013 plus Dexamethasone vs cc-5013 plus Low Dose Dexamethasone in Multiple Myeloma with Thalidomide plus Dexamethasone Salvage Therapy for Non-Responders

CTSU E1A05   Protocol  Randomized Phase III Trial of Consolidation Therapy with Bortezomib (Velcade®) - Lenalidomide (Revlimid®) - Dexamethasone (VRD) versus Bortezomib (Velcade®) - Dexamethasone (VD) for Patients with Multiple Myeloma Who Have Completed a Dexamethasone-Based Induction Regimen

CTSU E1A06  Protocol Treatment   Calendar Arm A  Arm B (closed 11/30/11)An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide Versus Melphalan, Prednisone and Lenalidomide in Newly Diagnosed Myeloma Patients Who Are Not Candidates for High-Dose Therapy

SWOG S0777 Protocol  Maintenance Calendar  (closure 2/1/12)A Randomized Phase III Trial of CC-5013 (Lenalidomide) and Low Dose Dexamethasone (LLD) Versus Bortezomib (PS-341), Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction, in Patients with Previously Untreated Multiple Myeloma Without an Intent for Immediate Autologous Stem Cell Transplant

Ovarian    

Pancreatic  

CTSU E6201    Protocol   A Phase III Randomized Study of Gemcitabine (fixed-dose rate infusion) and Oxaliplatin (NSC #266046) vs. Gemcitabine (fixed-dose rate infusion) vs. Gemcitabine (30-minute infusion) in Pancreatic Carcinoma

Prostate   

SWOG 9921      Protocol     Adjuvant Androgen Deprivation vs. Mitoxantrone Plus Prednisone Plus Androgen Deprivation in Selected High Risk Prostate Cancer Patients Following Radical Prostatectomy  (Press Release)

JPR.7     Protocol     A Phase III Randomized Trial Comparing Intermittent Versus Continuous Androgen Suppression for Patients with Prostate-Specific-Antigen Progression in the Clinical Absence of Distant Metastases Following Radiotherapy for Prostate Cancer

Renal    

CTSU CALGB 90206    Protocol   A Randomized Phase III Trial of Interferon Alfa-2B or Interferon Alfa-2B Plus Bevacizumab in Patients with Advanced Renal Carcinoma

Stomach/Esophageal   

CTSU C80101   Protocol    A Phase III Intergroup Trial of Adjuvant Chemoradiation after Resection of Gastric or Gastroesophageal Adenocarcinoma

Hepatic

NCCTG N0745 Protocol    (10/7/2011)  Phase I/II Randomized Study of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma

             Cancer Control                                                                                                                                                                                                                                                                                                                                SWOG E5597 Protocol    MD letter  Patient Letter - on    Patient Letter -off     Phase III   Chemo-prevention Trial of Selenium Supplementation in Persons with Resected Stage I Non-Small Cell Lung Cancer

SWOG S0715   Protocol  (2/1/11) Randomized Placebo-Controlled Trial of Acetyl L-Carnitine for the Prevention of Taxane-Induced Neuropathy

RTOG R0517 Protocol (closure 2/25/11) Randomized Phase III trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases from Lung, Breast and Prostate Cancer

Ovarian Function Failure

SWOG S0230   Protocol     (5/2011)Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Standard Adjuvant Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer